830 related articles for article (PubMed ID: 17267906)
1. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
3. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
[TBL] [Abstract][Full Text] [Related]
7. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
8. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
9. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
12. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
[TBL] [Abstract][Full Text] [Related]
14. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
15. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
[TBL] [Abstract][Full Text] [Related]
16. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
17. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
18. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
20. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
Li S; Kralovics R; De Libero G; Theocharides A; Gisslinger H; Skoda RC
Blood; 2008 Apr; 111(7):3863-6. PubMed ID: 18195094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]